Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Parent Project Muscular Dystrophy Holds 15th Annual Connect Conference In Atlanta
Patricia A. Furlong, Founding President and CEO of Parent Project Muscular Dystrophy (PPMD), the largest non-profit organization in the United States focused on finding a cure for Duchenne muscular dystrophy (Duchenne), announced that PPMD will be honoring United States Senator Johnny Isakson and the American Football Coaches Association (AFCA) with "Change It Champion" awards at the 2009 Connect Conference in Atlanta, Georgia on Saturday, June 27. Other award recipients include Darius Weems and Logan Smalley from the acclaimed documentary "Darius Goes West."

New Test For Safer Biomedical Research Results
In cancer research, as in most other biomedical sciences, they are playing a key role: living cells, kept in sterile plastic containers with red culture media populating incubators in laboratories around the world. But do researchers always know what is really living in their culture dishes? Under the microscope, different cell lines are almost impossible to distinguish from each other. When these important research objects stop growing without apparent reason - is it because of the manipulations by the scientists or because of an invisible viral or bacterial infection?
News of the day
Regional Center For Biodefense And Emerging Infectious Diseases Research Funded By NIH
A consortium of research centers in the Tri-state Region, including Albert Einstein College of Medicine of Yeshiva University, has received a $46 million grant to conduct research on emerging infectious diseases.
Sexual Health

New Data Show Cost Savings Achieved By Treating Mild And Moderate Alzheimer's Patients With Aricept(R)

Researchers attending the annual meeting of the International Society for Pharmacoeconomics & Outcomes Research (ISPOR), heard today that prescribing Aricept® (donepezil hydrochloride) as soon as patients are diagnosed with either mild or moderate Alzheimer"s disease saves the NHS money. The findings contradict the recommendation by NICE that these medicines are not cost effective in the early stages of the disease, a decision that has been the subject of much recent debate. The study shows that direct savings to the NHS over a ten year period average over ÷£4,000 per patient for those starting treatment in the mild stages of the disease. Total savings to society rise to ÷£7,100 per patient when the cost of care giver"s time is included. The average direct saving to the NHS over the same period for patients across the mild and moderate stages of the disease was estimated to be ÷£2,300 per patient, and for society ÷£4,800 when care giver"s time is taken into account. The study, sponsored by Eisai, uses more accurate calculations and more up-to-date costs of Alzheimer"s disease treatment than were used in the analyses undertaken by NICE, and the authors conclude that their findings indicate the decision taken by NICE to restrict treatment to patients with moderate Alzheimer"s disease was highly questionable. ISPOR


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009